miR-410 induces both epithelial–mesenchymal transition and radioresistance through activation of the PI3K/mTOR pathway in non-small cell lung cancer

Yue Yuan1, Hu Liao2, Qiang Pu2, Xixian Ke1, Xueting Hu1, Yongfang Ma1, Xinmei Luo1, Qianqian Jiang1, Yi Gong1, Min Wu3, Lunxu Liu2 and Wen Zhu1

Radiotherapy remains one of the major treatments for non-small cell lung cancer (NSCLC) patients; whereas intrinsic or acquired radioresistance limits its efficacy. Nevertheless, most studies so far have only focused on acquired resistance. The exact mechanisms of intrinsic radioresistance in NSCLC are still unclear. A few studies have suggested that epithelial–mesenchymal transition (EMT) is associated with radioresistance in NSCLC. However, little is known about whether the abnormal expression of specific microRNAs induces both EMT and radioresistance. We previously found that miR-410 has multiple roles as an oncomiRNA in NSCLC. In this study, we revealed that miR-410 overexpression promoted EMT and radioresistance, accompanied by enhanced DNA damage repair both in vitro and in vivo. Conversely, knockdown of miR-410 showed the opposite effects. We further demonstrated that PTEN was a direct target of miR-410 by using bioinformatic tools and dual-luciferase reporter assays, and the miR-410-induced EMT and radioresistance were reversed by PI3K, Akt, and mTOR inhibitors or by restoring the expression of PTEN in NSCLC cells. In addition, we preliminarily found that the expression of miR-410 was positively correlated with EMT and negatively associated with radioresistance. Therefore, miR-410 may serve as a potential biomarker or therapeutic target for NSCLC radiotherapy.

INTRODUCTION
Radiotherapy (RT), stereotactic body radiation therapy (SBRT) in particular, is a standard treatment for early-stage non-small cell lung cancer (NSCLC) patients who are unfit for surgery. Nevertheless, many patients diagnosed with NSCLC are already at an advanced stage, and RT/chemotherapy is recommended as radical or palliative treatment. However, similar to other epithelial tumor cells, NSCLC cells are often resistant to radiation. The intrinsic radioresistance of lung cancer cells leads to treatment failure in numerous NSCLC patients at the first RT. In addition, lung cancer cells may acquire radioresistance after primary RT; therefore, most patients show local recurrence after RT. Hence, intrinsic or acquired resistance to RT remains a major obstacle that limits the efficiency of the treatment for NSCLC. Nevertheless, most studies have focused on acquired resistance, and the exact mechanisms of intrinsic radioresistance in NSCLC are still unclear, likely owing to tumor heterogeneity and the various factors involved. A better understanding of the underlying mechanisms of intrinsic radioresistance may help to discover novel biomarkers or targets for improving the radioresponse of NSCLC.

Recently, a few studies have demonstrated that epithelial–mesenchymal transition (EMT) is positively associated with radioresistance in NSCLC. However, most of these studies have mainly focused on radiation-induced changes in EMT characteristics. It remains unclear whether the occurrence of EMT can result in radioresistance in NSCLC, and little is known about whether the abnormal expression of genes or pathways can affect both EMT and radiosensitivity in NSCLC. Notably, accumulating evidence has confirmed that EMT has a vital role in the regulation of NSCLC malignancy and is also of prognostic relevance. Therefore, exploring the molecular mechanisms underlying the regulation of both EMT and radioresistance will lay the basis for understanding whether EMT directly causes radioresistance. It is also important to discover novel mechanisms of radioresistance in NSCLC.

microRNAs (miRNAs) are important regulators in diverse biological processes of cancers, including tumor radiosensitivity, and they may serve as radiosensitizers or potential biomarkers in RT. Recently, miR-875-5p was determined to increase radiosensitivity and counteract EMT in prostate cancer. In NSCLC, it has been demonstrated that specific miRNAs are involved in the regulation of radioresistance or the EMT process. Recently, the only study suggested that miR-148b might affect the radioresponse and EMT in A549 cells. However, researches on the
miR-410 induces both epithelial-mesenchymal transition and radioresistance of miRNAs in NSCLC are still limited. High-quality, in-depth mechanistic studies are still needed to elucidate the role and potential mechanisms of specific miRNAs in regulating the NSCLC radioresponse. Moreover, research on how miRNAs mediate the association between EMT and radioresistance in NSCLC is still largely in its infancy, and further studies are needed to discover more about the underlying mechanisms. It also remains unclear whether the abnormal expression of miRNAs can regulate both EMT and radiosensitivity in NSCLC.

miR-410 is a member of the miR-379/410 miRNA cluster, which has crucial roles in various biological processes and cancer malignancies. In our previous studies, the upregulation of miR-410 was identified in NSCLC cells, including A549 and H1299 cells, and in NSCLC specimens. Moreover, overexpression of miR-410 was found to promote cell proliferation, metastasis, stemness, and chemoresistance by directly targeting SLC34A2 or Gsk3β and activating the Wnt/β-catenin pathway. Our previous studies demonstrated for the first time the role of miR-410 as an oncogene in tumorigenesis and the development of NSCLC. Likewise, miR-410 was found to increase the levels of phosphorylated Akt in NSCLC. Interestingly, A549 and H1299 cells with wild-type EGFR exhibited resistance to radiation and were used as radioresistant cells. Stabilization or upregulation of Slug by the inhibition of Gsk3β or activation of the β-catenin pathway could result in EMT and thus increase metastasis and chemoresistance in NSCLC. In addition, cancer stem cells (CSCs) and Akt phosphorylation are positively correlated with radioresistance and EMT. Consequently, mounting evidence indicates that miR-410 might be a promoter of EMT and radioresistance in NSCLC.

In the present study, we revealed that miR-410 induced both NSCLC EMT and radioresistance by targeting the PTEN/PI3K/mTOR axis in vitro and in vivo, and the promotion of radioresistance might be associated with enhanced DNA damage repair. Moreover, the data also suggested that miR-410-induced EMT might significantly contribute to the enhanced radioresistance, which might be a novel mechanism of radioresistance in NSCLC. Further investigation with NSCLC specimens also demonstrated that miR-410 was positively correlated with EMT. Collectively, our results indicate that miR-410 may be a potential biomarker or therapeutic target in NSCLC RT.

**RESULTS**

miR-410 promotes EMT and radioresistance in NSCLC cell lines

To understand the role of miR-410 in EMT and radioreponse in NSCLC cells, the endogenous levels of miR-410 in NSCLC cell lines (A549, H1299, PC9, and SPC-A1) and a non-cancerous bronchial epithelial cell line (HBE) were assessed first. The miR-410 expression levels were significantly higher in NSCLC cells than in HBE cells and were higher in A549 and H1299 cells than in PC9 and SPC-A1 cells (Fig. 1a). Thus, stable miR-410-overexpressing PC9 and SPC-A1 cell lines were established (termed as PC9-miR-410 and SPC-A1-miR-410) (Fig. 1b), and the previously established stable miR-410 knockdown A549 and H1299 cell lines (termed as A549-Inh and H1299-Inh) were also used to further explore the effects of miR-410 on EMT and the radioreponse in vitro. Interestingly, morphological changes from the typical spindle-like shape of A549 and H1299 cells to a cobblestone-like shape were observed upon miR-410 knockdown, whereas ectopic expression of miR-410 resulted in more PC9 and SPC-A1 cells with a spindle-like shape (Fig. 1c). Moreover, the protein levels of epithelial marker (E-cadherin) were notably increased, and mesenchymal markers (N-cadherin, Vimentin, and Slug) were significantly decreased in A549-Inh and H1299-Inh cells. Conversely, miR-410 overexpression caused the opposite effects (Fig. 1d). Similar results were shown by immunofluorescence assay of E-cadherin and vimentin (Fig. 1e, Supplemental Fig. S1).

Furthermore, miR-410 directly targeted PTEN in NSCLC cells

To identify the mechanism underlying the miR-410-induced EMT process and radioresistance, TargetScan, DIANA-microT-CDS, and miRanda were used to predict the targets of miR-410 (Fig. 3a). The potential targets predicted by all three algorithms (289 genes) were submitted for KEGG pathway analysis conducted with DAVID tools thereafter. The results showed that PTEN was among the 289 potential targets. Moreover, previous studies have shown that PTEN is closely related to EMT and radioresistance. In addition, KEGG analysis suggested that the predicted targets were involved in several cancer-related pathways (Fig. 3b, Supplemental Fig. S2). Among them, the PI3K/Akt and mTOR signaling pathways have been demonstrated to be closely associated with PTEN, which further indicated that PTEN might be a candidate target of miR-410. The direct interaction between miR-410 and the 3’-UTR of PTEN was then confirmed by a dual-luciferase reporter assay (Fig. 3c–e). Moreover, elevated protein levels of PTEN were observed in A549-Inh and H1299-Inh cells, whereas reduced expression of PTEN was detected in PC9-miR-410 and SPC-A1-miR-410 cells (Fig. 3f). However, the mRNA levels of PTEN showed no difference with the change in miR-410 expression (Supplemental Fig. S3). Collectively, these results confirmed that PTEN was a direct target of miR-410 and that it was posttranscriptionally regulated by miR-410 in NSCLC cells.

The PI3K/mTOR pathway contributed to miR-410-induced EMT and radioresistance in NSCLC cells

Studies have demonstrated that the activation of the PI3K/mTOR signaling pathway plays vital roles in regulating the EMT process or radiosensitivity in NSCLC. Therefore, based on the results above, we tested whether miR-410 might exert its biological functions by activating the PI3K/mTOR pathway. Of note, miR-410 overexpression in PC9 and SPC-A1 cells robustly increased the levels of phosphorylated Akt and mTOR, resulting in the enhanced phosphorylation of P70S6K and 4E-BP1. In contrast, miR-410 knockdown in A549 and H1299 cells remarkably decreased the levels of phosphorylated Akt, mTOR, P70S6K, and 4E-BP1 (Fig. 4a). These results suggested that miR-410 indeed activated the PI3K/mTOR pathway in NSCLC cells. Based on the results above that overexpression of miR-410 could promote both EMT and radioresistance in vitro, we next investigated the effects of specific blockade of the PI3K, Akt, or mTOR pathway on miR-410-induced EMT and radioresistance in miR-410-overexpressing PC9 and SPC-A1 cells. The effectiveness of different doses of PI3K inhibitor (LY294002), Akt inhibitor (MK-2206), and mTOR inhibitor (rapamycin) was confirmed first (Fig. 4b). Further results showed that treatment with the specific PI3K, Akt or mTOR inhibitor drastically decreased the expression of N-cadherin, Vimentin, and Slug while elevating the expression of E-cadherin in PC9-miR-410 and
miR-410 promotes EMT in NSCLC cell lines. 

**a** qRT-PCR analysis to quantify the endogenous levels of miR-410 in NSCLC cell lines (A549, H1299, PC9, and SPC-A1) and a non-cancerous bronchial epithelial cell line (HBE). U6 was used as a control. Experiments were performed in triplicate, and the relative expression levels were displayed as the mean ± SD.* \( P < 0.05; ** P < 0.01; *** P < 0.001. 

**b** qRT-PCR analysis of miR-410 levels in the indicated cell lines. (miR-410 and miR-NC, miR-410-overexpressing stable cell line and its matched NC control stable cell line). Experiments were performed in triplicate, and the relative expression levels were displayed as the mean ± SD.* \( P < 0.05; ** P < 0.01; *** P < 0.001. 

**c** Representative morphological images of the indicated NSCLC cells. Scale bar: 50 µm. 

**d** Western blotting analysis of EMT markers (E-cadherin, N-cadherin, Vimentin, and Slug) in the indicated cells. \( \beta \)-Actin was used as an internal control. 

**e** Immunofluorescence images of EMT markers (E-cadherin and vimentin) in the indicated cells. Scale bar: 20 µm.

Fig. 1  miR-410 induces both epithelial–mesenchymal transition.
miR-410 increased NSCLC cell radioresistance. 

**a** Clonogenic survival assays of the radioresponse in the indicated NSCLC cells. Dose–survival curves were created by survival fractions. Experiments were performed in triplicate, and the values were presented as the mean ± SD. *P < 0.05; **P < 0.01.

**b** Western blotting analysis of γ-H2AX in the indicated cells after 4 h of 4 Gy radiation.

**c** Representative immunofluorescence images of nuclear γ-H2AX foci (cell nuclei: blue; γ-H2AX foci: red) in the indicated cells after 4 h of 4 Gy radiation. Scale bar: 20 µm
miR-410 induces both epithelial–mesenchymal transition and radioresistance in NSCLC cells

SPC-A1-miR-410 cells (Fig. 4c). In addition, the protein levels and nuclear foci of γ-H2AX in PC9-miR-410 and SPC-A1-miR-410 cells were considerably increased after irradiation with the inhibition of the PI3K, Akt, or mTOR pathway (Fig. 4d, e). Similarly, the radioresistance of PC9-miR-410 and SPC-A1-miR-410 cells was significantly decreased after treatment with the PI3K, Akt, or mTOR inhibitor (Fig. 4f). Hence, these data illustrated that miR-410 promoted both the EMT process and radioresistance in NSCLC cells by activating PI3K/mTOR signaling.

PTEN was essential for miR-410-induced EMT and radioresistance in NSCLC cells

We further investigated whether PTEN is essential for PI3K/mTOR activation, thus resulting in the biological functions of miR-410 in NSCLC cells. The protein levels of PTEN were remarkably increased after transfecting 293T cells with miR-410 mimics or inhibitors or negative control in 293T cells. Experiments were performed in triplicate, and the values were presented as the mean ± SD. **P < 0.01; ***P < 0.001. The protein levels of PTEN in the indicated NSCLC cell lines.

Fig. 3 miR-410 directly targeted PTEN in NSCLC cells. a Venn diagrams of the number of genes identified as potential targets of miR-410 by three algorithms: TargetScan, miRanda, and DIANA-microT. b The KEGG analysis of potential miR-410 targets (n = 289) by DAVID bioinformatics resources. c Binding sites of PTEN 3′-UTR sequences with miR-410 seed sequences predicted by the algorithms TargetScan, miRanda, and DIANA-microT. d Sequence alignment between miR-410 sequences and PTEN 3′-UTR wild-type or PTEN 3′-UTR mutant sequences. Red indicates the sequences of the mutated miR-410 binding sites. e Relative luciferase activity of luciferase reporters containing wild-type or mutant PTEN 3′-UTR co-transfected with miR-410 mimics or inhibitors or negative control in 293T cells. Experiments were performed in triplicate, and the values were presented as the mean ± SD. **P < 0.01; ***P < 0.001. f The protein levels of PTEN in the indicated NSCLC cell lines.
Fig. 4  miR-410 promoted EMT and radioresistance via activation of the PI3K/mTOR pathway in NSCLC cells. a Western blotting analysis of total Akt, phospho-Akt, total mTOR, phospho-mTOR, total 4E-BP1, phospho-4E-BP1, total P70S6K, and phospho-P70S6K in the indicated cells. b Western blotting analysis of PI3K/mTOR pathway markers in the indicated cells treated with LY294002, MK-2206, or rapamycin at various concentrations. c Western blotting analysis of EMT markers in the indicated cells treated with LY294002 (20 μM), MK-2206 (10 μM), or rapamycin (1 μM). d Western blotting analysis of γ-H2AX in the indicated cells treated with LY294002 (20 μM), MK-2206 (10 μM), or rapamycin (1 μM) after exposure to 4 Gy of irradiation. e Representative immunofluorescence images of nuclear γ-H2AX foci (cell nuclei: blue; γ-H2AX foci: red) in the indicated cells treated with LY294002 (20 μM), MK-2206 (10 μM), or rapamycin (1 μM) after 4 h of 4 Gy radiation. Scale bar: 20 μm. f Clonogenic survival assays of the radioresponses in the indicated cells treated with LY294002 (20 μM), MK-2206 (10 μM), or rapamycin (1 μM). Experiments were performed in triplicate, and the values were presented as the mean ± SD. /▲, P < 0.05; /▲▲, P < 0.01; /▲▲▲, P < 0.001, treated with LY294002; ▼, treated with MK-2206; ▼▼, treated with rapamycin.
Fig. 5 Restoration of PTEN reversed miR-410-induced EMT and radioresistance in NSCLC cells. a Western blotting analysis of PTEN protein levels in 293T cells after transfection with pVax-PTEN/pVax. b qRT-PCR analysis of PTEN mRNA levels in 293T cells after transfection with #1, #2, #3-PTEN siRNA (siPTEN), or siRNA-NC (siPTEN-NC). Experiments were performed in triplicate, and the relative expression levels were displayed as the mean ± SD. *P < 0.05; **P < 0.01; ***P < 0.001. c Western blotting confirmation of the restoration of PTEN and the depletion of PTEN in indicated cells. d Western blotting analysis of EMT markers after restoration of PTEN and depletion of PTEN in the indicated cells. e Western blotting analysis of PI3K/mTOR pathway markers after restoration of PTEN and depletion of PTEN in the indicated cells. f Western blot analysis of γ-H2AX after restoration of PTEN and depletion of PTEN in the indicated cells after exposure to 4 Gy of irradiation. g Representative immunofluorescence images of nuclear γ-H2AX foci (cell nuclei: blue; γ-H2AX foci: red) after restoration of PTEN and depletion of PTEN in the indicated cells after 4 h of 4 Gy radiation. h Clonogenic survival assays of the radioresponse in the indicated cells after restoration of PTEN and depletion of PTEN. Experiments were performed in triplicate, and the values were presented as the mean ± SD. *P < 0.05; **P < 0.01; ***P < 0.001.
miR-410 overexpression or knockdown NSCLC cells, respectively (Fig. 5c). Indeed, restoration of PTEN expression in PC9-miR-410 and SPC-A1-miR-410 cells significantly inhibited the expression of N-cadherin, Vimentin and Slug and increased the expression of E-cadherin (Fig. 5d). Moreover, restoration of PTEN expression drastically decreased the levels of phosphorylated Akt, mTOR, P70S6K, and 4E-BP1 in PC9-miR-410 and SPC-A1-miR-410 cells (Fig. 5e). In addition, the expression levels of γ-H2AX and the radiosensitivity of PC9-miR-410 and SPC-A1-miR-410 cells were greatly increased after irradiation with the restoration of PTEN (Fig. 5f–h). Conversely, transfecting siPTEN in A549-Inh and H1299-Inh cells resulted in the opposite effects (Fig. 5d–g). In conclusion, these data demonstrated that PTEN was essential for miR-410-induced activation of the PI3K/mTOR pathway, thus resulting in enhanced EMT and radioresistance in NSCLC cells.

miR-410 promoted EMT and radioresistance in vivo and was associated with targeting PTEN while activating the PI3K/mTOR pathway

To determine whether miR-410 overexpression could promote EMT in vivo, SPC-A1-miR-410 cells were injected into the flanks of mice, and the A549-Inh subcutaneous tumor model established previously was also used.25 Consistent with the results in vitro, immunohistochemical staining of Vimentin and Slug was remarkably increased, whereas E-cadherin was significantly decreased in SPC-A1-miR-410 tumors (Fig. 6a). Accordingly, the protein levels of E-cadherin, N-cadherin, Vimentin, and Slug showed similar results. Moreover, elevated expression levels of phosphorylated Akt, mTOR, P70S6K, and 4E-BP1 were also observed in SPC-A1-miR-410 tumor tissues (Fig. 6b). Notably, both the protein levels and immunohistochemical staining of PTEN in the SPC-A1-miR-410 group exhibited significant downregulation (Fig. 6b, c). Conversely, investigations of A549-Inh tumors showed the opposite results (Fig. 6a–c). Thus, these data suggested that miR-410 overexpression could enhance the EMT process in vivo and was associated with targeting PTEN while activating the PI3K/mTOR pathway.

Moreover, to explore the effects of miR-410 overexpression on radioreponse in vivo, mice with subcutaneous tumors generated by SPC-A1-miR-410 and SPC-A1-miR-NC cells were randomly administered RT or mock RT. The SPC-A1-miR-410 tumors were considerably more radioresistant, as displayed by a shorter growth delay than the SPC-A1-miR-NC tumors (6.57 days (miR-410) vs. 11.14 days (miR-NC)) (Fig. 6d, Supplemental Table S1). In addition, the protein levels of γ-H2AX were greatly decreased in SPC-A1-miR-410 tumors treated with irradiation compared with SPC-A1-miR-NC tumors treated with irradiation (Fig. 6e). Altogether, these data demonstrated that miR-410 overexpression promoted radioresistance accompanied by enhanced DSB repair in vivo, and the enhanced radioresistance in vivo was also related to the activation of the PTEN/PI3K/mTOR axis.

miR-410 overexpression was correlated with EMT and low expression of PTEN in NSCLC specimens

In an effort to explore the clinical relevance of miR-410 and the EMT process, 62 NSCLC samples were collected. Then, the expression levels of miR-410 and EMT markers were examined, and the EMT phenotypes were classified based on our definition criteria (Fig. 7a). The high (>median, n = 31) and low (<median, n = 31) miR-410 expression groups were identified. Consequently, mesenchymal and EMT phenotypes were more likely found in patients with high miR-410 expression (Fig. 7b, Supplemental Table S2). High miR-410 expression was also linked with high expression of Vimentin (Supplemental Table S3). Taken together, these data suggested a positive correlation between miR-410 and the EMT process in NSCLC tissues.

Moreover, 80.65% of high miR-410 expression specimens showed low expression of PTEN, and 58.06% of low miR-410 expression specimens showed high expression of PTEN (Fig. 7c, d). This result indicated that the inverse correlation between miR-410 and PTEN was also clinically relevant in NSCLC.

Owing to the limited miR-410 expression data in cBioPortal, we explored the correlation between the expression of PTEN and EMT markers. Of note, in 360 cases of lung adenocarcinoma (TCGA, provisional) and 325 cases of lung squamous carcinoma (TCGA, provisional), the protein levels of PTEN were positively associated with E-cadherin levels (Fig. 7e). Hence, these data preliminarily further indicated the positive correlation between miR-410 and the EMT process in TCGA NSCLC specimens.

Furthermore, patients with high miR-410 expression tended to show poorer overall survival in 542 cases of lung adenocarcinoma tissues (TCGA_LUAD), whereas no significant difference was observed in 416 cases of lung squamous carcinoma tissues (TCGA_LUSC), which were analyzed by PROGmRNA2 (Supplemental Fig. S4). Thus, the results preliminarily showed that miR-410 overexpression is associated with poor prognosis in lung adenocarcinoma and indicated the role of miR-410 as an oncomiRNA, which was consistent with our previous studies.25

**DISCUSSION**

It has been reported that miRNAs are involved in the regulation of radiosensitivity and may be predictive biomarkers or therapeutic targets in cancer RT. However, little is known about whether the abnormal expression of miRNAs promotes both EMT and radioresistance. In the current study, we revealed the roles and the underlying mechanism of miR-410 in inducing both EMT and radioresistance, which also suggested that miR-410-induced EMT might significantly contribute to the enhanced radioresistance.

The occurrence of EMT elicits alterations in cell morphology and the activation of “EMT-inducing transcription factors”, including the Snail family, which results in changes in EMT-associated markers. Consistent with these findings, in our study, morphological changes into spindle-like shapes were observed in PC9-miR-410 and SPC-A1-miR-410 cells, accompanied by a remarkable reduction in E-cadherin levels and an increase in N-cadherin, Vimentin, and Slug levels. Conversely, the opposite effects were found in A549-Inh and H1299-Inh cells. Hence, our data demonstrated that miR-410 overexpression promoted the EMT process in NSCLC cells.

Only a few studies have shown that EMT is positively correlated with radioresistance in NSCLC. On the one hand, NSCLC cells that survived radiation and grew in spheres showed mesenchymal phenotypes, and inhibition of radiation-induced EMT could enhance the radiosensitivity of cells. Upregulation of mesenchymal markers and reduction of epithelial markers were also observed in NSCLC specimens after chemoradiotherapy. On the other hand, mesenchymal lung cancer cells were found to display increased radioresistance, which suggested that EMT might in turn contribute to radioresistance in NSCLC. In our study, assessments of the radioreponse in miR-410 overexpression or knockdown cells demonstrated that miR-410 could increase radioresistance, as well as promote EMT, which also indicated that the occurrence of EMT was accompanied by radioresistance in NSCLC cells.

DSBs are the most crucial lesions of radiation-induced DNA damage. The rapid phosphorylation of H2AX at Ser139 to produce γ-H2AX is a sensitive and reliable indicator of the cellular response to DSBs. In the present study, we found that the protein levels of γ-H2AX were increased 4 h after IR compared with non-irradiated cells. Moreover, the γ-H2AX levels were significantly lower in PC9-miR-410 and SPC-A1-miR-410 cells 4 h after radiation, whereas the opposite results were observed in A549-Inh and H1299-Inh cells. The data suggested that miR-410-increased radioresistance might be associated with enhanced DSB repair in NSCLC cells. However, whether miR-410 directly regulates...
Fig. 6 Overexpressing miR-410 promoted EMT and radioresistance in vivo and was associated with the PTEN/PI3K/mTOR axis. 

a Immunohistochemical (IHC) staining of EMT markers in tumors recovered from mice transplanted with the indicated cell lines. Scale bars, 50 μm. 

b Western blotting analysis of PTEN, EMT markers, and PI3K/mTOR pathway markers in the indicated tumor tissues. 

c IHC staining of PTEN in the indicated tumor tissues. Scale bars, 50 μm. 

d The means of tumor volumes normalized to the original volumes in the indicated groups. Dotted line, the endpoint of four times the original volume. Tumor volume quadrupling time of the indicated groups. SPC-A1 miR-410 and miR-NC tumors were treated with a weekly 10 Gy dose of radiotherapy (RT) for 3 weeks or mock RT (0 Gy). The values were shown as the means ± SD (n = 7/group). * P < 0.05; ** P < 0.01; *** P < 0.001. 

e Western blotting analysis of γ-H2AX in the indicated tumor tissues.
genes involved in the major pathways of DNA damage repair (NHEJ and HR) or in the DNA damage response (DDR)-associated processes, including the cell cycle and apoptosis, still need to be further explored.

A single miRNA is able to target multiple genes by binding to the 3′-untranslated regions (3′-UTRs), which leads to the degradation of mRNA or the inhibition of mRNA translation.\(^{14}\) In our previous studies, we revealed that miR-410 promoted NSCLC tumorigenesis, development, stemness, and metastasis by targeting SLC34A2 and Gsk3\(\beta\).\(^{24,25}\) miR-410 was also reported to enhance proliferation by targeting BDR7 in NSCLC.\(^{26}\) In the current study, three bioinformatic databases were used to predict the targets of miR-410. The results showed that PTEN was among the potential targets. Further KEGG analysis suggested that the
potential targets of miR-410 were involved in cancer-related pathways, including Ras, PI3K/Akt, mTOR, and Wnt. Studies have demonstrated that the PI3K/Akt and mTOR pathways are closely associated with PTEN.36 Therefore, we hypothesized that PTEN might be a candidate target of miR-410. In the present study, the direct interaction between miR-410 and PTEN was confirmed by dual-luciferase reporter assays, and PTEN was found to be posttranscriptionally regulated by miR-410. These results indicated that PTEN was a direct target of miR-410 in NSCLC cells. Similarly, in a recent study, PTEN was also reported as the target of miR-410, and human umbilical cord mesenchymal stem cell-derived extracellular vesicles increased the growth of lung adenocarcinoma (LUAD) cells by transferring miR-410 to cells and subsequently decreasing the protein level of PTEN.42 However, the study mainly focused on exploring the effects and mechanism of hUCMSCs on LUAD growth without addressing the functions of miR-410 in EMT, radioresistance or the PI3K/mTOR pathway in lung cancer.

PTEN is a well-characterized negative regulator of the PI3K/Akt signaling pathway.36 Loss of PTEN in NSCLC drives the hyper-activation of PI3K/Akt and downstream mTOR, thus regulating multiple cellular functions.43 Studies also found that PTEN could mediate NSCLC EMT and radioresistance, respectively.34,44 Furthermore, in NSCLC, growing evidence proved that the activation of the PI3K/Akt/mTOR pathway could induce EMT,19 and play important roles in radioresistance as the downstream of the EGFR pathway.38,44 Dual inhibition of PI3K/Akt and mTOR enhanced the radioreponse by regulating the DDR process in various cancers, including NSCLC.45 Therefore, we hypothesized that miR-410 exerts its biological effects on EMT and radioresistance by activating the PI3K/mTOR pathway. Indeed, we found that overexpression of miR-410 in NSCLC cells robustly increased the levels of phosphorylated Akt, mTOR, P70S6K, and 4E-BP1. Conversely, knockdown of miR-410 remarkably decreased the levels of these markers. Our results further showed that treatment with a specific PI3K, Akt, or mTOR inhibitor drastically inhibited miR-410-induced EMT and radioresistance in PC9-miR-410 and SPC-A1-miR-410 cells. In addition, restoration of PTEN expression in PC9-miR-410 and SPC-A1-miR-410 cells significantly decreased miR-410-induced EMT and radioresistance, whereas transfecting siPTEN in A549-Inh and H1299-Inh cells resulted in the opposite effects. Consequently, our data demonstrated that PTEN was essential for miR-410-induced activation of the PI3K/mTOR pathway, which resulted in promoting both EMT and radioresistance in NSCLC cells (Fig. 7B). These results also indicated that PTEN played an important role in the biological functions induced by miR-410. Recently, Zhang et al.46 reported that miR-410-3p exerted oncogenic functions in prostate cancer via the PTEN/AKT/mTOR pathway. Yang et al.47 showed that loss of IncRNA OIP5-A51 induced miR-410 accumulation and regulated its target KLF10/PTEN/AKT-mediated cellular behaviors in multiple myeloma cells. These data also showed the association between miR-410 and the PTEN/AKT/mTOR axis in tumors.

Studies showed that the expression of E-cadherin increased the radiosensitivity of breast cancer cells.48 Moreover, miR-205 inhibited DNA damage repair and acted as a radiosensitizer by targeting ZEB1 in breast cancer cells,49 whereas the promotion of DDR by ZEB1 might be the mechanism underlying the correlation between EMT and radioresistance.50 Hence, the roles of EMT-related markers and transcription factors in the radioreponse suggested that EMT might be one of the causes of radioresistance in cancers. Furthermore, a study on the tumor microenvironment of NSCLC demonstrated that the activation of the IGF1R/PI3K/AKT pathway by hypoxia could induce EMT, which might subsequently enhance radioresistance.51 Consequently, we inferred that in NSCLC cells, radioresistance with enhanced DNA damage repair might be promoted by the miR-410-induced EMT process. However, to clearly understand the correlation between miR-410-induced EMT and radioresistance, a separate and effective tracing system is needed to monitor the EMT process because the EMT phenotype is reversible and transient. For instance, Fischer and Zheng et al.52,53 established effective tracking systems to monitor the EMT process in mice, thus clarifying the role of EMT in metastasis and chemoresistance. This issue will be explored in the future.

Further investigations in vivo showed that the levels of mesenchymal markers were remarkably increased, whereas the levels of E-cadherin and PTEN were significantly decreased, accompanied by the elevated expression of phosphorylated PI3K/mTOR pathway markers in SPC-A1-miR-410 tumors. The opposite observations were showed in A549-Inh tumors. Moreover, SPC-A1-miR-410 tumors were considerably more radio-resistant, as demonstrated by a shorter growth delay and a reduction in γ-H2AX levels. Thus, these data suggested that miR-410 overexpression could enhance the EMT process and radio-resistance in vivo, which was associated with the PTEN/PI3K/mTOR axis. Likewise, other miRNAs (e.g., miR-200c17) have been observed to regulate the radioreponse in lung cancer subcutaneous tumor models. Limitations still exist by using pathway inhibitors as radiosensitizers in NSCLC.38,54 Thus, our results suggest that miR-410 may serve as a potential target to improve the radioreponse of NSCLC.

In our previous studies, the upregulation of miR-410 was observed in NSCLC specimens.20,21 The results confirmed the role of miR-410 as an oncogene in NSCLC. Consistent with these findings, high miR-410 expression tended to be associated with poorer overall survival in lung adenocarcinoma patients in the current study, which further indicated the oncogenic role of miR-410. Moreover, mesenchymal and EMT phenotypes and high vimentin expression were more likely to be found in NSCLC patients with high miR-410 expression, and the protein levels of PTEN were positively associated with E-cadherin levels in TCGA NSCLC specimens. These results preliminarily suggested a positive correlation between miR-410 and EMT. However, except for the positive correlation between negative E-cadherin expression and low differentiation in 62 NSCLC samples, the expression of Vimentin and Slug showed no significant differences with the pathology characteristics. This might be owing to the limited number of samples. On the basis of the association between EMT and radioresistance, these data also preliminarily indicate that miR-410 might be a potential target of radioreponse in NSCLC. However, it needs to be explored further in post-RT samples. In summary, we revealed that miR-410 induced both NSCLC EMT and radioresistance by targeting the PTEN/PI3K/mTOR axis in vitro and in vivo, and the promotion of radioresistance was associated with enhanced DNA damage repair. Moreover, the data also suggested that miR-410-induced EMT might significantly contribute to the enhanced radioresistance, which might be a novel mechanism of radioresistance in NSCLC. Further investigation in NSCLC specimens also demonstrated that miR-410 was positively correlated with EMT. Therefore, our results indicate that miR-410 may serve as a potential biomarker or therapeutic target in NSCLC RT, which might increase the treatment efficiency while inhibiting EMT-related malignancy.

**MATERIALS AND METHODS**

Cell culture, lentiviruses, and stable cell lines

The NSCLC cell lines A549, H1299, PC9, and SPC-A1, the human embryonic kidney cell line 293T (293T) and the normal lung epithelial cell line HBE were purchased from American Type Culture Collection (Manassas, VA, USA). A549, H1299, PC9, and SPC-A1 cells were maintained in RPMI 1640 (Invitrogen, Carlsbad, CA, USA); 293T and HBE cells were cultured in Dulbecco’s modified Eagle’s medium (Invitrogen) supplemented with 10% fetal bovine serum (Invitrogen) at 37°C in 5% CO₂.
Recombinant lentiviruses expressing miR-410 or the scrambled control were constructed and packaged by HanBio (Shanghai, China). The stable miR-410-overexpressing and control SPC-A1 and PC9 cell lines were established by lentivirus infection and puromycin (Merck Millipore, Burlington, MA, USA) selection as previously described. The expression efficiencies of miR-410 were quantified by quantitative real-time PCR (qRT-PCR). The miR-410-knockdown stable A549 and H1299 cell lines (A549-Inh and H1299-Inh) were established and confirmed previously.

Tissue specimens
A total of 62 clinical NSCLC specimens used in this study were obtained from the Department of Thoracic Surgery from patients histopathologically and clinically diagnosed at West China Hospital by procedures approved by the Medical Ethical Committee of West China Hospital, Sichuan University (Chengdu, China). Clinical information of the 62 NSCLC cases is presented in Supplemental Table S4.

Quantitative real-time PCR
qRT-PCR was performed as previously described. Total RNA was extracted using TRIzol Reagent (Invitrogen) and was reverse-transcribed with the PrimeScript RT reagent Kit (Takara, Dalian, China). The primers for qRT-PCR were commercially synthesized (RiboBio Co., Ltd, Guangzhou, China). The primers for qRT-PCR were as follows: PTEN forward, 5′- TGGTGTCGCTGCAACTGAAGG-3′; PTEN reverse, 5′-GGGAGGGGAGAACCAATG-3′; qRT-PCR was performed with the SYBR Green Real-Time PCR Master Mix Kit protocol (Bio-Rad, Hercules, CA, USA) on a CFX96 Real-Time System (Bio-Rad) to quantitate the miR-410 or PTEN mRNA level using U6 or β-actin as an internal control, respectively. The relative expression of miR-410 and PTEN was calculated by the 2^−ΔΔCt method.

Western blotting
Western blotting was performed as described previously. Primary antibodies against β-actin, E-cadherin, N-cadherin, γ-H2AX (Ser139), PTEN, PI3K, Akt, and p-Akt (Ser473) were used. To validate the direct interaction between miR-410 and the 3′-UTR of PTEN, 293T cells were seeded in 96-well plates the day before transfection and then co-transfected with ~100 ng of wild-type or mutant PTEN 3′-UTR and with miR-410 mimics (50 nM) or inhibitors (100 nM) or negative control (50 nM) (RiboBio Co. Ltd). Luciferase activity was detected 24 h after transfection and assayed by using the Dual-Glo Luciferase Reporter System (Promega). All experiments were performed in triplicate. Firefly luciferase activity was normalized to the internal Renilla luciferase activity.

Xenografted tumor model in vivo
To evaluate the effects of miR-410 on EMT and radioresistance in vivo, a nude mouse xenograft model was established. Five-week-old male athymic BALB/c nude mice (BEIJING HFK BIOSCIENCE CO. LTD, Beijing, China) were maintained in a specific pathogen-free (SPF) environment. SPC-A1-miR-410 or SPC-A1-miR-NC cells (5 × 10^6) were injected subcutaneously into the right flanks of mice. One tumor per mouse was inoculated. Tumor volume (in mm^3) was determined by caliper measurements performed twice a week and calculated by using the modified ellipse formula (volume = π/6 × length × widths^2). When the xenograft tumor volumes reached ~200 mm^3, mice were randomly assigned to mock RT or weekly 10 Gy dose of RT for 3 weeks. The tumor growth delay time (in days) was calculated by subtracting the average tumor volume quadrupling time for irradiated tumors from the average tumor volume quadrupling time for non-irradiated tumors. The tumor volume quadrupling time was calculated for each individual animal and then averaged for each group (n = 7/group). The volumes of tumors reached four times the original volume, the mice were killed, and their tumors were harvested for immunohistochemical and western blotting analyses. All experiments involving mice were performed according to the requirements of the Institutional Animal Care and Use Committee of West China Hospital, Sichuan University (Chengdu, China).

Immunohistochemical analysis
The tissues of xenograft tumors or clinical NSCLC samples were fixed in 4% paraformaldehyde and routinely dehydrated. Paraffin-embedded tissue samples were cut into 4 μm sections and deparaffinized, rehydrated, and then incubated with primary antibodies against E-cadherin, PTEN (Cell Signaling Technology), Vimentin (Zen BioScience) or Slug (Santa Cruz Biotechnology), respectively. Immunostaining was developed with 3′-diaminobenzidine tetrahydrochloride (DAB) and co-stained with hematoxylin. Immunostaining images were acquired with a Zeiss AX10 Imager A2 microscope (Carl Zeiss).
The results of IHC were scored independently by two observers in terms of both the intensity and the extent of staining. The staining intensity was graded as 0, negative staining; 1, weak staining; 2, moderate staining; and 3, strong staining. The proportion of positively stained cells per specimen was determined as follows: 0 for no positively stained cells; 1 for <10%; 2 for 10–50%; and 3 for >50% of the examined cells. The histological score (H-score) was calculated by the proportion score × intensity score. An H-score ≥4 was considered high expression, and ≤3 was considered low expression. A final total score was graded as negative (−), weak (+), moderate (+++), or strong (+++).

For the EMT phenotype assessment, the epithelial phenotype was defined as high E-cadherin expression and low expression of all mesenchymal phenotype biomarkers, whereas the mesenchymal phenotype was identified by high expression of one of the mesenchymal phenotype biomarkers together with low E-cadherin expression; the epithelial-to-mesenchymal phenotype was defined as high expression of both E-cadherin and mesenchymal phenotype biomarkers, whereas the remaining cases were not specified.57

Analysis of NSCLC data in PROGmiRV2 or cBioPortal for TCGA database
TCGA is available from the website of the Cancer Genomics Browser of the University of California, Santa Cruz (https://genome-cancer.ucsc.edu). The PROGmiRV2 and cBioPortal for Cancer Genomics are open-access downloaded biodatabases, providing visualization and analysis tools for large-scale cancer genomics datasets. Both portals collected records from the TCGA database. In total, 542 lung adenocarcinoma cases and 416 lung squamous cell carcinoma cases were performed by PROGmiRV2 to preliminarily analyze the correlation between the expression of miR-410 and overall survival. A total of 360 lung adenocarcinoma cases and 325 lung squamous cell carcinoma cases were performed by cBioPortal to preliminarily analyze the correlation between the protein expression of PTEN and EMT markers.

Statistical analysis
Data were analyzed with GraphPad Prism 6 or SPSS 22.0 software. Significant differences between two groups were analyzed using two-tailed Student’s t test. The correlation between miR-410 expression and EMT phenotype, EMT marker expression or PTEN expression was analyzed by r test. All values were presented as the mean ± SD. P < 0.05 (\(\uparrow\)), P < 0.01 (\(\uparrow\uparrow\)), and P < 0.001 (\(\uparrow\uparrow\uparrow\uparrow\)) were considered statistically significant.

ACKNOWLEDGEMENTS
This study was partly supported by The National 863 Plan Project (2012AA020802) and the National Science and Technology Major Projects of New Drugs (2012ZX09103301-009).

AUTHOR CONTRIBUTIONS
Y. Yuan performed the research; W. Zhu contributed to the conception and design, financial support, administrative support, and provision of materials; Y. Yuan and W. Zhu analyzed, interpreted the data and wrote the manuscript; H. Liao, Q. Pu, X. Ke, X. Hu, Y. Ma, X. Luo, Q. Jiang, Y. Gong and M. Wu provided technical support; H. Liao, Q. Pu, and L. Liu contributed to the study materials of clinical specimens. All authors read and approved the final manuscript.

ADDITIONAL INFORMATION
The online version of this article (https://doi.org/10.1038/s41392-020-0182-2) contains supplementary material, which is available to authorized users.

Competing interests: The authors declare no competing interests.

REFERENCES
1. Wink, K. C. J., van Baardwijk, A., Troost, E. G. C. & de Ruyschrier, D. Nodal recurrence after stereotactic body radiotherapy for early stage non-small cell lung cancer: incidence and proposed risk factors. Cancer Treat. Rev. 56, 8–15 (2017).
2. Timmerman, R. D. et al. Stereotactic body radiation therapy for operable early-stage lung cancer: findings from the NSRG oncology RT0G 0618 trial. JAMA Oncol. 4, 1263–1266 (2018).
3. Grootjans, W. et al. PET in the management of locally advanced and metastatic NSCLC. Nat. Rev. Clin. Oncol. 12, 395–407 (2015).
4. Heineman, D. J., Daniels, J. M. & Schreurs, W. H. Clinical staging of NSCLC: current evidence and implications for adjuvant chemotherapy. Ther. Adv. Med. Oncol. 9, 599–609 (2017).
5. Sanil, T. et al. Ionizing radiation regulates the expression of AMP-activated protein kinase (AMPK) in epithelial cancer cells: modulation of cellular signals regulating cell cycle and survival. Radiother. Oncol. 102, 459–465 (2012).
6. Sato, K., Shimokawa, T. & Imai, T. Difference in acquired radioresistance induction between repeated photon and particle irradiation. Front. Oncol. 9, 1213 (2019).
7. Rosenzweig, K. E. & Gomez, J. E. Concurrent chemotherapy and radiation therapy for inoperable locally advanced non-small-cell lung cancer. J. Clin. Oncol. 35, 6–10 (2017).
8. Li, L. et al. Targeting DNA damage response in the radio(Chem)otherapy of non-small cell lung cancer. Int. J. Mol. Sci. 17, 839 (2016).
9. Bayo, J. et al. Jumonji inhibitors overcome radioresistance in cancer through changes in H3K4 methylation at double-strand breaks. Cell Rep. 25, 1040–1050. e1045 (2018).
10. Gomez-Casal, R. et al. Non-small cell lung cancer cells survived ionizing radiation treatment display cancer stem cell and epithelial-mesenchymal transition phenotypes. Mol. Cancer 12, 94 (2013).
11. Kang, J. et al. Rhammetin and cirsimolar induce radiosensitization and inhibition of epithelial-mesenchymal transition (EMT) by miR-34a-mediated suppression of Notch-1 expression in non-small cell lung cancer cell lines. J. Biol. Chem. 288, 27343–27357 (2013).
12. Kwon, O. S. et al. BCL2 induced by LAMTOR3/MAPK is a druggable target of chemoradioresistance in mesenchylmous lung cancer. Cancer Lett. 403, 48–58 (2017).
13. Xu, J. et al. NatD promotes lung cancer progression by preventing histone H4 serine phosphorylation to activate Slug expression. Nat. Commun. 8, 928 (2017).
14. Bracken, C. P., Scott, H. S. & Goodall, G. J. A network-biology perspective of microRNA function and dysfunction in cancer. Nat. Rev. Genet. 17, 719–732 (2016).
15. Korpela, E., Vespriini, D. & Liu, S. K. MicroRNA in radiotherapy: miRage or mirador? Br. J. Cancer 112, 777–782 (2015).
16. El Beazzawy, R. et al. miR-875-5p counteracts epithelial-to-mesenchymal transition and enhances radiation response in prostate cancer through repression of the EGF-R/ERK1 axis. Cancer Lett. 395, 53–62 (2017).
17. Cortez, M. A. et al. Therapeutic delivery of miR-200c enhances radiosensitivity in lung cancer. Mol. Ther. 22, 1494–1503 (2014).
18. Shi, L. et al. miR-127 promotes EMT and stem-like traits in lung cancer through a feed-forward regulatory loop. Oncogene 36, 1631–1643 (2017).
19. Luo, H. & Liang, C. MicroRNA-148b inhibits proliferation and the epithelial-mesenchymal transition and increases radiosensitivity in non-small cell lung carcinomas by regulating ROCK1. Exp. Ther. Med. 15, 3609–3616 (2018).
20. Huang, Q. Predictive relevance of ncRNAs in non-small-cell lung cancer patients with radiotherapy: a review of the published data. Biomark. Med. 12, 1149–1159 (2018).
21. Long, L. et al. Tissue-specific and exosomal miRNAs in lung cancer radiotherapy: from regulatory mechanisms to clinical implications. Cancer Manag. Res. 11, 4413–4424 (2019).
22. Qian, P. et al. The Dlk1-Gtl2 locus preserves LT-HSC function by inhibiting the PISK-mTOR pathway to restrict mitochondrial metabolism. Cell Stem Cell 18, 214–228 (2016).
23. Valdmanis, P. N. et al. Upregulation of the microRNA cluster at the Dlk1-Dio3 locus in lung adenocarcinoma. Oncogene 34, 94–103 (2015).
24. Zheng, X. et al. MicroRNA-410 acts as oncogene in NSCLC through down-regulating SLC34A2 via activating Wnt/β-catenin pathway. Oncotarget 7, 14569–14585 (2016).
25. Ke, X. et al. MiR-410 induces stemness by inhibiting Gsk3β but upregulating β-catenin in non-small cells lung cancer. Oncotarget 8, 11356–11371 (2017).
26. Li, D. et al. MicroRNA-410 promotes cell proliferation by targeting BRD7 in non-small cell lung cancer. FEBS Lett. 589, 2218–2223 (2015).
27. Das, A. K. et al. Non-small-cell lung cancers with kinase domain mutations in the epidermal growth factor receptor are sensitive to ionizing radiation. Cancer Res. 66, 9601–9608 (2006).

miR-410 induces both epithelial–mesenchymal transition... Yuan et al.
miR-410 induces both epithelial-mesenchymal transition...

Yuan et al.

28. Yang, H. J. et al. Investigation of radiation-induced transcriptome profile of radioresistant non-small cell lung cancer A549 cells using RNA-seq. PLoS ONE 8, e59319 (2013).

29. Kao, S. H. et al. GSK3β controls epithelial-mesenchymal transition and tumor metastasis by CHIP-mediated degradation of Slug. Oncogene 33, 3172–3182 (2014).

30. Yang, S. et al. FOXF3 promotes tumor growth and metastasis by activating Wnt/β-catenin signaling pathway and EMT in non-small cell lung cancer. Mol. Cancer 16, 124 (2017).

31. Tang, Y. et al. Radiation-induced miR-208a increases the proliferation and radioresistance by targeting p21 in human lung cancer cells. J. Exp. Clin. Cancer Res. 35, 7 (2016).

32. Yue, J. et al. Epigenetic silencing of miR-483-3p promotes acquired gefitinib resistance and EMT in EGFR-mutant NSCLC by targeting integrin β3. Oncogene 37, 4300–4312 (2018).

33. Atsumi, Y. et al. ATM and SIRT6/SNF2H mediate transient H2AX stabilization when DSBs form by blocking HUWE1 to allow efficient γH2AX foci formation. Cell Rep. 13, 2728–2740 (2015).

34. Zhao, M. et al. Dual roles of miR-374a by modulated c-Jun respectively targets CCND1-inducing PI3K/AKT signal and PTEN-suppressing Wnt/β-catenin signaling in non-small-cell lung cancer. Cell Death Dis. 9, 78 (2018).

35. Toulany, M. & Rodemann, H. P. Phosphatidylinositol 3-kinase/Akt signaling as a key mediator of tumor cell responsiveness to radiation. Semin. Cancer Biol. 35, 180–190 (2015).

36. Haddadi, N. et al. PTEN/PI3K/AKT pathway and therapeutic targets in non-small cell lung cancer. Cancer Sci. 109, 3519–3531 (2018).

37. Legras, A. et al. Epithelial-to-mesenchymal transition and MicroRNAs in lung cancer. Cancers (Basel) 9, 14 (2017).

38. Storozhuk, Y. et al. Metformin inhibits growth and enhances radiation response of non-small cell lung cancer (NSCLC) through ATM and AMPK. Br. J. Cancer 108, 2021–2032 (2013).

39. Shihue, T. & Weinberg, R. A. EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. Nat. Rev. Clin. Oncol. 14, 611–629 (2017).

40. Shintani, Y. et al. Epithelial to mesenchymal transition is a determinant of sensitivity to chemoradiotherapy in non-small cell lung cancer. Ann. Thorac. Surg. 92, 1794–1804 (2011).

41. Morgan, M. A. & Lawrence, T. S. Molecular pathways: overcoming radiation resistance by targeting DNA damage response pathways. Clin. Cancer Res. 21, 2898–2904 (2015).

42. Dong, L. et al. Human umbilical cord mesenchymal stem cell-derived extracellular vesicles promote lung adenocarcinoma growth by transferring miR-410. Cell Death Dis. 9, 218 (2018).

43. Pérez-Ramírez, C. et al. PTEN and PI3K/AKT in non-small-cell lung cancer. Pharmacogenomics 16, 1843–1862 (2015).

44. Florczuk, M., Szpechcinski, A. & Chorostowska-Wynimko, J. miRNAs as biomarkers and therapeutic targets in non-small cell lung cancer: current perspectives. Target. Oncol. 12, 179–200 (2017).

45. Liu, T. et al. Dual PI3K/mTOR inhibitors, GSK2126458 and PKI-587, suppress tumor progression and increase radiosensitivity in nasopharyngeal carcinoma. Mol. Cancer Ther. 14, 429–439 (2015).

46. Zhang, Y. et al. miR-410-3p promotes prostate cancer progression via regulating PTEN/AKT/mTOR signaling pathway. Biochem. Biophys. Res. Commun. 503, 2459–2465 (2018).

47. Yang, N. et al. LncRNA OIP5-AS1 loss-induced microRNA-410 accumulation regulates cell proliferation and apoptosis by targeting KLF10 via activating PTEN/PI3K/AKT pathway in multiple myeloma. Cell Death Dis. 8, e2975 (2017).

48. Theys, J. et al. E-Cadherin loss associated with EMT promotes radiosensitivity in human tumor cells. Radiother. Oncol. 99, 392–397 (2011).

49. Zhang, P. et al. miR-205 acts as a tumour radiosensitizer by targeting ZEB1 and Ubc13. Nat. Commun. 5, 5671 (2014).

50. Zhang, P. et al. ATM-mediated stabilization of ZEB1 promotes DNA damage response and radiosensitivity through CHK1. Nat. Cell Biol. 16, 864–875 (2014).

51. Kim, I. G. et al. Hypoxia-inducible transgelin 2 selects epithelial-to-mesenchymal transition and gamma-radiation-resistant subtypes by focal adhesion kinase-associated insulin-like growth factor 1 receptor activation in non-small-cell lung cancer cells. Cancer Sci. 109, 3519–3531 (2018).

52. Fischer, K. R. et al. Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature 527, 472–476 (2015).

53. Zheng, X. et al. Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature 527, 525–530 (2015).

54. Konstantinidou, G. et al. Dual phosphoinositide 3-kinase/mammalian target of rapamycin blockade is an effective radiosensitizing strategy for the treatment of non-small cell lung cancer harboring K-RAS mutations. Cancer Res. 69, 7644–7652 (2009).

55. Hu, S. et al. Antagonism of EGFR and Notch limits resistance to EGFR inhibitors and radiation by decreasing tumor-initiating cell frequency. Sci. Transl. Med. 9, eaas0339 (2017).

56. Blau, J. et al. A preclinical study combining the DNA repair inhibitor Dabtib with radiotherapy for the treatment of melanoma. Neoplasia 16, 835–844 (2014).

57. Ren, S. et al. Epithelial phenotype as a predictive marker for response to EGFR-TKIs in non-small cell lung cancer patients with wild-type EGFR. Int. J. Cancer 135, 2962–2971 (2014).

58. Goswami, C. P. & Nakshatri, H. PROGmiR: a tool for identifying prognostic miRNA biomarkers in multiple cancers using publicly available data. J. Clin. Bioinformatics 2, 23 (2012).

59. Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401–404 (2012).